Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best drug stocks to buy right now. In a report released on September 12, Simon Baker CFA from Redburn Atlantic maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and set a price target of $143.00.

Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector

In other news, Gilead Sciences, Inc. (NASDAQ:GILD) announced on August 26 that it attained marketing authorization for Yeytuo (lenacapavir) from the European Commission (EC).

Yeytuo is the company’s twice-yearly injectable HIV-1 capsid inhibitor that is used as “pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg”.

Management reported that Yeytuo is the first and only twice-yearly PrEP option to be approved for use in the 27 member states of the European Union, including Iceland, Norway, and Liechtenstein.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.